CALIDI BIOTHERAPEUTICS INC (CLDI)

AMEXHealth CareBiotechnologySnapshot 2026-10-23

$0.64-0.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge CALIDI BIOTHERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-88.32
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-76.8

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital via equity warrants and offerings	A supporting condition in CALIDI BIOTHERAPEUTICS INC's published investment case. The stated target is maintain liquidity with controlled equity issuance.	Under Pressure	excessive dilution or failure to raise needed capital	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage capital via equity warrants and offeringsPublished status: Under Pressure
File IND for CLD-401 in Q4 2026Direct metric needs a verified mapping
Reduce operating losses toward -$4.19M per quarterOperating income: $-4.15M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-97.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

CALIDI BIOTHERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making clinical-stage biotech with a speculative growth profile, not an established earnings compounder. The thesis is in a watch state, with low confidence and volatile management execution; recent performance remains below its industry group.

What's priced into CALIDI BIOTHERAPEUTICS INC

The evidence does not provide a valuation measure or a clear account of market expectations, so whether CLDI is cheap or expensive versus peers cannot be assessed. The snapshot does show weak fundamentals and elevated risk, but it does not establish how much of those concerns is already reflected in the market.

What the fundamentals likely do

Near term, operating losses and a high risk of another earnings miss remain concerns, though management reduced general and administrative expenses in Q1 and Q2 2026 versus the prior year. Over the multi-year view, the key progress is whether CLDI files the CLD-401 IND application by the end of 2026 and advances its pipeline beyond preclinical work; the September listing-rule notice adds risk.

What CALIDI BIOTHERAPEUTICS INC hinges on

The thesis depends on timely delivery of the CLD-401 filing and evidence that RedTail pipeline work can advance toward clinical milestones, while expense control continues. Near-term guidance, employment data, and results from sector bellwethers could also affect the operating backdrop, but the snapshot gives no company-specific clinical outcomes.

Bottom line

Over the next 1 to 3 years, CLDI remains a low-confidence, high-risk development story with some cost-control progress but no clinical milestone delivery yet. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

CALIDI BIOTHERAPEUTICS INC (CLDI)

What could strengthen or challenge CALIDI BIOTHERAPEUTICS INC’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

CALIDI BIOTHERAPEUTICS INC outlook in detail

What kind of bet this is

What's priced into CALIDI BIOTHERAPEUTICS INC

What the fundamentals likely do

What CALIDI BIOTHERAPEUTICS INC hinges on

Bottom line

Analyst view

Price-target changes

Bottom line